Companies › Kerecis
1 active drug program in 1 registered trial: 1 Phase 4; Cardiovascular; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MariGen (Intact Fish Skin Graft) Biological wound dressing derived from fish skin | – | Phase 4 | Venous Leg Ulcer (VLU) | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06693570 | MariGen (Intact Fish Skin Graft) | Phase 4 | Venous Leg Ulcer (VLU) | Cardiovascular | Nov 2026 |
No annotated target.
–
Cell Biopeutics Resources Sdn Bhd TR Therapeutics AOTI Beijing Inno Medicine Nectero Medical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.